1. Home
  2. HQ vs ANL Comparison

HQ vs ANL Comparison

Compare HQ & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$22.22

Market Cap

562.7M

Sector

N/A

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$11.37

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQ
ANL
Founded
2018
2004
Country
Singapore
United States
Employees
44
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
562.7M
611.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
HQ
ANL
Price
$22.22
$11.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
1.3M
189.5K
Earning Date
05-05-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.29
$0.88
52 Week High
$45.00
$17.25

Technical Indicators

Market Signals
Indicator
HQ
ANL
Relative Strength Index (RSI) 51.36 56.64
Support Level $21.30 $9.00
Resistance Level $45.00 $12.24
Average True Range (ATR) 3.52 1.35
MACD -0.90 0.17
Stochastic Oscillator 25.11 93.35

Price Performance

Historical Comparison
HQ
ANL

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: